The U.S. Environmental Protection Agency (EPA) is proposing to ease emissions limits on ethylene oxide (EtO), a move that highlights a growing tension at the heart of healthcare supply chain resilience.
EtO is used to sterilize roughly half of all medical devices in the U.S., including catheters, surgical kits, and implantable products. Its ability to penetrate complex packaging and sterilize heat-sensitive materials makes it indispensable to modern medical manufacturing.
The proposal would roll back elements of stricter Biden-era regulations designed to significantly reduce emissions of the chemical, which is classified as a carcinogen linked to cancers such as lymphoma and leukemia. Federal regulators say the change is intended to avoid unintended consequences, particularly disruptions to the availability of essential medical devices.
Past efforts to tighten EtO controls have already led to temporary sterilization facility closures, raising concerns about supply continuity. Industry stakeholders warn that overly restrictive rules could further constrain capacity, slow production, and limit access to critical products.
Environmental and public health advocates, however, argue that easing standards could increase long-term exposure risks for workers and surrounding communities. The issue highlights a fundamental policy crossroads: how to maintain a reliable supply of sterile medical devices while addressing legitimate public health concerns.
Why It Matters
EtO remains the primary method for sterilizing complex, heat-sensitive medical devices. That makes sterilization a critical, and vulnerable, link in the supply chain.
The broader takeaway is that healthcare supply chain resilience isn't just about efficiency or cost. It increasingly requires balancing competing risks across clinical care, financial performance, and public health.
